Poor-prognostic advanced Germ Cell Tumors
|
|
- Angelica Dickerson
- 6 years ago
- Views:
Transcription
1 Poor-prognostic advanced Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Metastatic GCT: Prognosis (IGCCC) Good prognosis Intermediate prognosis Poor prognosis J Clin Oncol 1997, 15:
2 Poor prognosis metastatic NSGCT Definition: any of: Primary tumor site: Mediastinal Extra-pulmonary visceral mets: Yes Tumor marker before chemo: hcg: > AFP > LDH 15% of metastatic NSGCT Cure rate: 50% > 10 x norm J Clin Oncol 1997, 15: Poor-risk GCT: A standard established in BEP > 4 PVB: DFS (p<0.05) and OS (p<0.05) Better tolerance (neurotoxicity) 4 BEP= standard Presented by: Karim Fizazi 2
3 4 BEP are not 5, 6, or 7 Giving additional cycles of BEP: Did not demonstrate any improvement in outcome Increases the risk of: severe paresthesia, auditive toxicity, neutropenic fever, and fertility troubles Giving > 4 BEP makes your patient at a 2% risk of meeting this: 2% risk of secondary acute leukemia if etoposide > 2 g/m 2 80% mortality a rate similar to that after a cobra bite. Kollmansberger, J Clin Oncol 1998, 16:
4 Phases III of HD chemotherapy + transplant in first-line poor-prognosis NSGCT T87 French trial (n=115) (Droz 2007) 4 PVeBV vs 4 PVeBV + HD CisEC Intergroup US trial: (n=219) (Motzer 2007) 4 BEP vs BEP + 2 HD-CEC EORTC trial: (n=137) (Daugaard 2011) 4 BEP vs VIP + HD-VIP The only trial to include poor-risk pts only Poor-risk NSGCT: T87 phase III trial Poor-risk NSGCT (n= 115) PVeBV: 4 cycles: Cisplatin 40 mg/m 2 x 5 Etoposide 100 mg/m 2 x 5 Bleomycin 30 U/w Vinblastine 0.2 mg/kg d1 1 cycle/ 3 weeks PVeBV: 4 cycles + high dose CT (PEC): etoposide 350 mg/m 2 x 5 cisplatin 40 mg/m 2 x 5 cyclophosphamide 1600 mg/m 2 x 5 Bone marrow transplant 4
5 T87 phase III trial HD= Double dose cisplatin + etoposide + cyclop + autograft Median follow-up: 9.7 years Probability Treatment PVeBV Figure 1 Overall Survival PVBV+PEC p= Years HD Chemotherapy arm Droz et al., Eur Urol 2007, 51: Phase III intergroup US trial Intermediate/poor risk pts n= 219 R 4 BEP 2 BEP + 2 HDCT (CBDCA, VP16, CPM) Time to treatment failure Overall survival Motzer, J Clin Oncol 2007; 25:
6 Poor prognosis NSGCT: US Phase III trial 4 BEP vs 2 BEP + 2 HDCT n= 219 pts (intermediate or poor-risk) HDCT= CBDCA, VP16, CPM Time to treatment failure Overall survival Motzer, J Clin Oncol 2007; 25: Phase III EORTC 4 BEP vs sequential HD VIP in IGCCCG poor-risk NSGCT n= 137 (222 planned) FFS p=0.057 R 4 BEP HD VIP + stem cell OS p=0.36 Daugaard G et al. Ann Oncol 2011;22:
7 Poor prognosis NSGCT: Randomized trials Chemotherapy BEP x 4 v BEP 200 x 4 BEP x 4 v BEP/PVB x 4 BEP x 4/EP x 2 v BOP/VIP-B BEP x 4 v VIP x 4 P 200 VBE x ¾ v P 200 VBE x 2 + P 200 EC Number of patients Favorable response rates (%) Conclusion Double dose cisplatin not superior and more toxic Alternating regimen not superior and more toxic Dose dense alternating regimen not superior and more toxic Substitution of ifosfamide for bleomycin not superior and more toxic High dose chemotherapy not superior and more toxic Reference Nichols 1991 de Wit 1995 Kaye 1998 Nichols 1998 Droz 2007 BEP x 4 v BEP x 3 + CaEC BEP x 4 v CISCA/VB High dose chemotherapy not superior and more toxic Alternating regimen not superior and more toxic Motzer 2007 Culine 2008 Courtesy of S. Culine Poor-risk GCT: 25 years of negative phase 3 trials VIP: Nichols, J Clin Oncol 1998, 16: CISCA/VB: Culine, J Clin Oncol 2007, 26: HD: Motzer, J Clin Oncol 2007; 25: HD: Daugaard, Ann Oncol 2011; 22:
8 Poor prognosis NSGCT: where did we stand until 2013? No progress demonstrated by randomized trials in the last 25 years However, general improvement observed (from 45% to 60% survival): Patient education (lower tumor burden)? Referral to well-trained centers (Collette JNCI 1999)? Improvement in the management of chemotherapy side effects? Improvement in surgery? Others? Management of pts at high risk of ARDS: «Very high risk NSGCT» ARDS 13/15 (87%) Death from ARDS Longterm survivor Extensive lung mets Dyspnea or po2< /10 (30%) Total 16/25 10/15 2/10 12/25 4/15 (27%) 4/10 (40%) 8/25 Massard C, Ann Oncol
9 Is the number of treated cases important for outcome? n= 380 patients from the EORTC/MRC phase III trial testing BEP vs BOP-VIP 65% had a poor-prognosis according to IGCCCG 49 European institutions: 26 treated <5 patients Cox analysis for PFS and OS Collette L et al. J Natl Cancer Inst 1999;91: Kaplan-Meier estimate of failure-free survival according to total accrual of patients by the treating institution in trial 30895/TE13. Failure-Free Survival Collette L et al. JNCI J Natl Cancer Inst 1999;91: Oxford University Press 9
10 OS Does experience matter? (EORTC Phase III trial) 20% Collette L et al. JNCI J Natl Cancer Inst 1999;91: Survival according to tumor marker decline in Poor-prognosis GCT Tumor markers assessed at Day 21 Tumor markers assessed at Day 42 Probability IGCCCG - POOR RISK Overall Survival Time to Normalization FAVORABLE UNFAVORABLE p= Years Fizazi, J Clin Oncol 2004, 22: Motzer, J Clin Oncol 2007; 25: Presented by: Karim Fizazi 10
11 Calculation of tumor marker decline Decline rates are calculated using a logarithmic formula : M0=initial marker value; M1=marker value at 3 w; MN=Normal value Tumor marker decline = 3 A / B A = log(m0)-log(mn) B = log(m0)-log(m1) Patients can then be classified into 4 categories as follows : AM Normal at cycle 1 and at cycle 2 BM Abnormal at cycle 1 and Normalization at cycle 2 CM Abnormal cycle 1 and TNM < TM DM Abnormal cycle 1 and TNM TM or abnormal and increasing marker at cycle 2 Cut-off points (TM) vary for each marker: TAFP = 9 w, ThCG = 6 w A favorable pattern of decline is defined by hcg and AFP being both A, B, or C. Fizazi, J Clin Oncol 2004, 22: GETUG 13 Phase III design Median follow-up: 4.1 years (0.3 ; 8.8 years) n=263 n=254 Poor-risk GCT (IGCCCG) Registration 1st BEP Favorable decline Day 21: Tumor marker n=51 Unfavorable decline n=203 R 4 BEP (total) Dose-dense regimen n=105 4 BEP (total) n=98 Presented by: Karim Fizazi 11
12 GETUG 13: Dose-dense regimen BEP 1 Cisplatin 20 mg/m 2 /d d1-5 Etoposide 100 mg/m 2 /d d1-5 Bleomycin 30 u/w Paclitaxel-BEP + Oxaliplatin + G-CSF / 3 weeks 2 cycles Paclitaxel 175 mg/m 2 d1 BEP as above Oxaliplatin 130 mg/m 2 d10 G-CSF 263 µg/d (excepted chemo days) Cisplatin, Ifosfamide, Bleomycin + G-CSF / 3 weeks 2 cycles Cisplatin 100 mg/m 2 d1 Ifosfamide 2g/m 2 d10,12,14 Mesnum Bleomycin 25 U/d d10-14 (continuous IV) G-CSF as above Presented by: Karim Fizazi Primary endpoint: PFS in randomized patients with an unfavorable decline At risk 100% 80% 60% 40% 20% 0% HR: 0.66 [ ] p= Years year PFS: 59% vs 48% Unfav-Dose-dense Unfav-BEP Unfav-BEP Unfav-DoseDense cned: 63 vs 46 pts Fizazi K, Lancet Oncol 2014 (in press) 12
13 OS in randomized patients with an unfavorable decline At risk 100% 80% 60% 40% 20% 0% Years HR: 0.78 (0.46 ; 1.31), p= year OS: 73% vs 65% Unfav-Dose-dense Unfav-BEP Unfav-BEP Unfav-DoseDense Alive: 78 vs 66 pts Presented by: Karim Fizazi Fizazi K, Lancet Oncol 2014 (in press) 100% Outcome according to tumor marker decline PFS 100% OS At risk 80% 60% 40% 20% 0% Years Fav-BEP Unfav-BEP Unfav-Dose-dense Unfav-DoseDense Unfav-BEP Fav-BEP At risk 80% 60% 40% 20% 0% Years Fav-BEP Unfav-BEP Unfav-Dose-dense Unfav-DoseDense Unfav-BEP Fav-BEP Fav-BEP vs Unfav-BEP: 3-year PFS: 70% vs 48% HR=0.66 (0.49 ; 0.88), p=0.01 Fav-BEP vs Unfav-BEP: 3-year OS: 84% vs 65% HR=0.65 (0.45 ; 0.95), p=0.024 Fizazi K, Lancet Oncol 2014 (in press) 13
14 Salvage chemotherapy Survival Stage I Metastatic stages (IGCCCG) - Good pronosis - Intermediate prognosis - Poor pronosis Salvage setting post-first-line CT 99% 95% 80% 50% 25% Prognostic classification: metastatic GCT + failure to first-line cisplatin-based chemotherapy n= 1984 pts PFS Prognostic factors: - Histology: NS vs Seminoma - Tumor site: Testis/Extra/Med - Visceral metastases - Previous response - Progression-free interval (3m) - hcg (1000) - AFP (1000) Prognostic score J Clin Oncol 2010, 28:
15 Salvage treatment for patients failing first-line chemotherapy 4 cycles of a 3-drug regimen: Containing cisplatin and ifosfamide Third drug: Vinblastine (VeIP) Etoposide (VIP) Paclitaxel (TIP) Gemcitabine (GIP) G-CSF required + surgery for residual masses Cure achieved in ~25-50% Evidence based on large phase II experiences Salvage HD chemotherapy + transplant Phase II trials: With single autograft reported in the 1990 s (carboplatin, etoposide, +/- cyclophosphamide) With sequential autografts (TICE at Memorial, HD-VIP in Germany, TAXIF) Two phase III trials: IT94: Single HD vs conventional (Pico 2005) German trial: Single HD vs Sequential HD (Lorch 2012) 15
16 HD chemotherapy for 2 nd line: IT94 phase III trial n= Refractory or relapsed GCT R VeIP: 2 cycles Response No response 2 VeIP 1 VeIP + CARBOPEC IT94: Event-free survival Pico et al., Ann Oncol 2005, 16:
17 IT94: Overall survival Conclusion: No demonstrated benefit for single HD chemotherapy Pico et al., Ann Oncol 2005, 16: Indiana experience with sequential HD n= 184 pts, salvage (135 second line), retrospective 2 cycles of Carboplatin 750 mg/m 2 x3 + Etoposide 700 mg/m 2 x3 DFS: - 94/135 (70%) second-line pts - 18/40 (45%) cisplatin-refractory pts 3 toxic deaths + 3 leukemia Einhorn L, New Engl J Med 2007, 357:
18 Sequential HD: TICE regimen (MSKCC) Taxol-Ifo x 2, then HD Carbo-VP16 x 3 Overall survival n= 37 pts Poor-Pc salvage GCT: - Non testis primary - No previous CR - 2 lines No toxic death PFS: 18/37 (49%) Motzer, J Clin Oncol 2000, 18: Single vs Sequential HD chemotherapy for salvage n= 230 pts OS R 1 VIP + 3 HD CE 3 VIP + 1 HD CEC Accrual stopped for toxicity: 4% vs 16% toxic death rate OS border line better for sequential Sequential CT better tolerated Lorch A et al., J Clin Oncol 2007, 25: Lorch A et al., J Clin Oncol 2012; 30:
19 We still need to demonstrate that sequential HD is superior to standard doses The TIGER trial: TIP vs TICE Conclusion Prognostic role of tumor marker decline clearly established Early intensification in pts with unfavorable decline after 1 BEP improves PFS (GETUG 13): new standard treatment HD chemotherapy in the salvage setting: Cures (some) patients Lack of predictive factor to identify who benefits Sequential > single HD (less toxic deaths) Sequential HD > standard-dose still to be demonstrated (Tiger) 19
20 Support Movember! 20
Germ Cell Tumors. Karim Fizazi, MD, PhD Institut Gustave Roussy, France
Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Surveillance for stage I GCT NSGCT A 26 year-old patient had a orchiectomy revealing embryonal carcinoma (40%), seminoma (40%) and
More informationNICaN Testicular Germ Cell Tumours SACT protocols
Reference No: Title: Author(s) Ownership: Approval by: Systemic Anti-Cancer Therapy (SACT) Guidelines for Germ Cell Tumours Dr Audrey Fenton Consultant Medical Oncologist, Dr Vicky Coyle Consultant Medical
More informationFellow GU Lecture Series, Testicular Cancer. Asit Paul, MD, PhD 02/06/2018
Fellow GU Lecture Series, 2018 Testicular Cancer Asit Paul, MD, PhD 02/06/2018 Rare cancer worldwide, approximately 1% of all male cancers There is a large difference among ethnic/racial groups. Rates
More informationFellow GU Lecture Series, Testicular Cancer. Asit Paul, MD, PhD 02/06/2018
Fellow GU Lecture Series, 2018 Testicular Cancer Asit Paul, MD, PhD 02/06/2018 Rare cancer worldwide, approximately 1% of all male cancers There is a large difference among ethnic/racial groups. Rates
More informationTesticular Cancer. Prof. Dr. Jörg Beyer Physician-in-Chief Department of Oncology, University Hospital Berne, Switzerland. Mail:
Testicular Cancer Prof. Dr. Jörg Beyer Physician-in-Chief Department of Oncology, University Hospital Berne, Switzerland Mail: joerg.beyer@insel.ch The menue: Epidemiology & Staging Ongoing discussions
More informationManagement of Stage Ic-IV Malignant Ovarian Germ Cell Tumours
Management of Stage Ic-IV Malignant Ovarian Germ Cell Tumours Michael J Seckl Charing Cross Hospital Campus of Imperial College NHS Healthcare Trust Imperial College London, UK 9-12th June 2010 Caravaggio
More informationThe Contemporary Role of Chemotherapy for Advanced Testis Cancer: A Systematic Review of the Literature
EUROPEAN UROLOGY 61 (2012) 1212 1221 available at www.sciencedirect.com journal homepage: www.europeanurology.com Collaborative Review Testis Cancer The Contemporary Role of Chemotherapy for Advanced Testis
More informationPopulations Interventions Comparators Outcomes Individuals: With previously untreated germ cell tumors
Hematopoietic Cell Transplantation in the Treatment of Germ Cell (80135) (Formerly Hematopoietic Stem Cell Transplantation in the Treatment of Germ Cell ) Medical Benefit Effective Date: 04/01/13 Next
More informationIntensive Chemotherapy with Autologous Peripheral Blood Stem Cell Transplantation During a 10-Year Period in 64 Patients with Germ Cell Tumor
Biology of Blood and Marrow Transplantation 12:355-365 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1203-0013$32.00/0 doi:10.1016/j.bbmt.2005.11.006 Intensive Chemotherapy
More informationHematopoietic Cell Transplantation in the Treatment of Germ Cell Tumors (GCT)
Hematopoietic Cell Transplantation in the Treatment of Germ Cell Tumors (GCT) Policy Number: 8.01.35 Last Review: 7/2017 Origination: 7/2002 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas
More informationREVIEW ARTICLE. Summary. Introduction
JBUON 2017; 22(2): 306-311 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE An overview of high dose chemotherapy with autologous stem cell rescue
More informationIs High-Dose Chemotherapy After Primary Chemotherapy a Therapeutic Option for Patients With Primary Mediastinal Nonseminomatous Germ Cell Tumor?
Biology of Blood and Marrow Transplantation 12:1085-1091 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1210-0001$32.00/0 doi:10.1016/j.bbmt.2006.06.008 Is High-Dose Chemotherapy
More informationHematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors. Original Policy Date
MP 7.03.27 Hematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature
More informationMULTIDISCIPLINARY GENITOURINARY ONCOLOGY COURSE
MULTIDISCIPLINARY GENITOURINARY ONCOLOGY COURSE Case 2 Testicular Cancer Nuno Sineiro Vau Medical Oncologist Champalimaud Foundation, Lisbon October 2017 Male, 36 year-old, sales manager. Past medical
More informationHematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors
Hematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors Policy Number: Original Effective Date: MM.07.020 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 05/24/2013
More informationHematopoietic Cell Transplantation in the Treatment of Germ- Cell Tumors
Medical Policy Manual Transplant, Policy No. 45.38 Hematopoietic Cell Transplantation in the Treatment of Germ- Cell Tumors Next Review: August 2018 Last Review: December 2017 Effective: January 1, 2018
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationHematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors
Hematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors Policy Number: Original Effective Date: MM.07.020 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 12/16/2016
More informationGeneral introduction to the concepts of chemotherapy NVvO Basiscursus Oncologie 5 maart 2015
General introduction to the concepts of chemotherapy NVvO Basiscursus Oncologie 5 maart 2015 Martijn Lolkema, MD/PhD Medical Oncologist Erasmus MC Cancer Institute Chemotherapy: targeting proliferation
More informationTesticular cancer and other germ cell tumours. London Cancer Jonathan Shamash
Testicular cancer and other germ cell tumours London Cancer 2018 Jonathan Shamash Background Testicular germ cell tumours are the commonest cancers of young men Overall they are curable but long term side
More informationTESTICULAR CANCER Updated March 2016 by Dr. Safiya Karim (PGY-5 Medical Oncology Resident, University of Toronto)
TESTICULAR CANCER Updated March 2016 by Dr. Safiya Karim (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Aaron Hansen (Staff Medical Oncologist, University of Toronto) DISCLAIMER:
More informationTESTICULAR CANCER has been one of the major success
Intensive Induction Chemotherapy With CBOP/BEP in Patients With Poor Prognosis Germ Cell Tumors By J.A. Christian, R.A. Huddart, A. Norman, M. Mason, S. Fossa, N. Aass, E.J. Nicholl, D.P. Dearnaley, and
More informationLancet 2008; 372 : CDF. N Engl J Med Aug 28;349(9): J Clin Oncol May 15;19(10): Cancer Nov 1;113(9):2471-7
Tumour Group: UROLOGY Renal Palliative Sunitinib 1 st line therapy Lancet. 1999 Jan 2;353(9146):14-7. Pazopanib 1 st line therapy J Clin Oncol. 2010 28(06):1061-1068 Everolimus 2 nd or 3 rd line in adv./metas.rcc
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationViable Germ Cell Tumor at Postchemotherapy Retroperitoneal Lymph Node Dissection. Can We Predict Patients at Risk of Disease Progression?
2700 Viable Germ Cell Tumor at Postchemotherapy Retroperitoneal Lymph Node Dissection Can We Predict Patients at Risk of Disease Progression? Philippe E. Spiess, MD 1 Nizar M. Tannir, MD 2 Shi-Ming Tu,
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation in the Treatment of Germ File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_in_the_treatment_of_germ_cell_tumor
More informationHematopoietic Cell Transplantation in the Treatment of Germ Cell Tumors
Hematopoietic Cell Transplantation in the Treatment of Germ Cell Tumors Policy Number: Original Effective Date: MM.07.020 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 4/27/2018 Section:
More informationHigh-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors Lawrence H. Einhorn, M.D., Stephen D. Williams, M.D.,
More informationBrain Metastases Associated With Germ Cell Tumors May Be Treated With Chemotherapy Alone
Brain Metastases Associated With Germ Cell Tumors May Be Treated With Chemotherapy Alone Anna Hardt, MRCP 1 ; Jonathan Krell, MRCP 2 ; Peter D. Wilson, FRCP 1 ; Victoria Harding, MRCP 3 ; Simon Chowdhury,
More informationLong-Term Outcome for Men With Teratoma Found at Postchemotherapy Retroperitoneal Lymph Node Dissection
Original Article Long-Term Outcome for Men With Teratoma Found at Postchemotherapy Retroperitoneal Lymph Node Dissection Robert S. Svatek, MD 1, Philippe E. Spiess, MD 2, Debasish Sundi, BS 1, Shi-ming
More informationResection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer
Turkish Journal of Cancer Vol.31/ No. 2/2001 Resection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer AHMET ÖZET 1, ALİ AYDIN YAVUZ 1, MURAT BEYZADEOĞLU
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationKEY WORDS Testis cancer Germ cell cancer Tandem autotransplant
Biology of Blood and Marrow Transplantation 13:778-789 (2007) 2007 American Society for Blood and Marrow Transplantation 1083-8791/07/1307-0001$32.00/0 doi:10.1016/j.bbmt.2007.02.013 Utility of Single
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationEAU GUIDELINES ON TESTICULAR CANCER
EAU GUIDELINES ON TESTICULAR CANCER (Limited text update March 2015) P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg
More informationGERM-CELL TUMOURS. ESMO Preceptorship on Adolescents and Young Adults with cancer Lugano, May 2018
ESMO Preceptorship on Adolescents and Young Adults with cancer Lugano, 11-12 May 2018 GERM-CELL TUMOURS Giannis Mountzios MSc, PhD Medical Oncology University of Athens School of Medicine Athens, Greece
More informationTESTICULAR CANCER IS THE MOST
CLINICAL REVIEW CLINICIAN S CORNER Medical Treatment of Advanced Testicular Cancer Darren R. Feldman, MD George J. Bosl, MD Joel Sheinfeld, MD Robert J. Motzer, MD TESTICULAR CANCER IS THE MOST common
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationEAU GUIDELINES ON TESTICULAR CANCER
EAU GUIDELINES ON TESTICULAR CANCER (Limited text update March 2018) P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna (Vice-chair), N. Nicolai,
More informationTestis tumors. Richard Epstein
Testis tumors Richard Epstein TKCC/SVH, August 5 2016 Testis cancer - Remains virtually the only solid (nonhaematologic) metastatic tumour that is routinely curable by drug therapy. What we will discuss
More informationOriginal article. Introduction
Annals of Oncology 7: 1015-1021, 1996. O 1996 Kluwer Academic Publishers. Printed in the Netherlands. Original article A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin,
More informationState of the Science: Current status of research relevant to GCT GCT Survivors Weekend April 16, 2011
State of the Science: Current status of research relevant to GCT GCT Survivors Weekend April 16, 2011 Jubilee Brown, M.D. Associate Professor UT M.D. Anderson Cancer Center Ovarian Cancer 21,880 new cases
More informationPage 1 of 17 TABLE OF CONTENTS
Page 1 of 17 TABLE OF CONTENTS Suspicious Testicular Cancer. Page 2 nseminomatous Germ Cell Tumor (NSGCT): workup and clinical stage Page 3 Seminoma: workup and clinical stage... Page 4 Clinical Stage
More informationManagement of Testicular Cancer
Management of Testicular Cancer Christian Kollmannsberger MD FRCPC Clinical Professor Div. of Medical Oncology BC Cancer - Vancouver Cancer Centre Dept. of Medicine, University of British Columbia Associate
More informationOriginal article. J. Pont, 1 ' 2 C. Bokemeyer, 3 A. Harstrick, 4 F. Sellner, 5 H. Greinix 6 & F. Stoiber 1 ' 7
Annals of Oncology 8:,. Kluwer Academic Publishers. Printed in the Netherlands. Original article Chemotherapy for germ cell tumors relapsing after highdose chemotherapy and stem cell support: A retrospective
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationThere have been substantial advances in the treatment of testicular
The new england journal of medicine Review Article Dan L. Longo, M.D., Editor Testicular Cancer Discoveries and Updates Nasser H. Hanna, M.D., and Lawrence H. Einhorn, M.D. There have been substantial
More informationPrognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours
Article no. bjoc.1999.0534 Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours SD Fosså 1, SP Stenning 2, A Gerl 3, A Horwich
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationUK CAA Oncology Certification Charts
UK CAA Oncology Certification Charts 1. Colorectal 2. Malignant Melanoma 3. Germ Cell Tumour of Testis 4. Renal Cell Carcinoma 5. Breast Carcinoma 6. Non-small Cell Lung Cancer Note: All Class 1 cases
More informationCommon disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,
Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000
More informationReview. Is 'one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. K. Fizazi & L.
Annals of Oncology 11: 133-149. 2000. S 2000 Klimer Academic Publishers. Printed in the Netherlands. Review Is 'one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationEAU GUIDELINES ON TESTICULAR CANCER
EU GUIDELINES ON TESTICULR CNCER (Limited text update March 2017) P. lbers (Chair), W. lbrecht, F. lgaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi,. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg Introduction
More informationTesticular tumours are uncommon but constitute an
09010:Layout 1 3/18/10 9:26 PM Page E19 CONSENSUS GUIDELINE Canadian consensus guidelines for the management of testicular germ cell cancer Lori Wood, MD; * Christian Kollmannsberger, MD, FRCSC; Michael
More informationMr Hrouda Date Review date: May 2014
GERM CELL TUMOURS Section by: Dr Philip Savage, Dr Cathryn Brock and Professor Michael Seckl Version: Germ Cell Tumour Regimens v3.02 NWLCN 28May12 Section last updated: 28 th May 2012 Last Corrected 28
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationTesticular Cancer Update Nabil Adra 1, Lawrence H. Einhorn 1
Review Article - Clinical Advances in Hematology & Oncology Testicular Cancer Update Nabil Adra 1, Lawrence H. Einhorn 1 1 Division of Hematology & Medical Oncology - Melvin & Bren Simon Cancer Center,
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationUncommon secondary tumour of the stomach
Uncommon secondary tumour of the stomach B. Bancel, Hôpital CROIX ROUSSE LYON Bucharest Nov 2013 Case report 33-year old man Profound mental retardation and motor disturbances (sequelae of neonatal meningeal
More informationOptimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More information9:00 a.m. Germ Cell Tumors (GCT): Beyond BEP Activity No L04-P
Oncology Pharmacy Specialty Sessions, Part II Wednesday, October 19 9:00 a.m. noon Convention Center: Rooms 306 & 307 Part of the professional development program for the recertification of board-certified
More informationTesticular Cancer. J. Richard Auman, MD. James J. Stark, MD. Jerry Singer, MD. September 19, 2008
Testicular Cancer J. Richard Auman, MD James J. Stark, MD Jerry Singer, MD September 19, 2008 Testicular Cancer From mystery to far-advanced disease: a remarkable case Case Presentation. 23 y. o. male
More informationHigh-Dose Chemotherapy in Adult Solid Tumors and Lymphoproliferative Disorders: The Need for Randomized Trials
High-Dose Chemotherapy in Adult Solid Tumors and Lymphoproliferative Disorders: The Need for Randomized Trials JEAN-PIERRE DROZ, a STÉPHANE CULINE, b PIERRE BIRON, a ANDREW KRAMAR C a Department of Medical
More informationSurvival Analysis in Clinical Trials: The Need to Implement Improved Methodology
Survival Analysis in Clinical Trials: The Need to Implement Improved Methodology Lucinda (Cindy) Billingham Professor of Biostatistics Director, MRC Midland Hub for Trials Methodology Research Lead Biostatistician,
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationLate recurrence of an embryonal carcinoma of the testis. Case report
Late recurrence of an embryonal carcinoma of the testis. Case report Luminita Gurguta 1 *, Mihai V. Marinca 1, 2 1 Medical Oncology Department, Regional Institute of Oncology, Iasi, Romania, 2 Department,
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationTHERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra,
THERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra, Slovakia Lancet. 1966;2(7471):979-86. First standard treatment:
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationmetastatic nonseminomatous testicular cancer: a multivariate analysis
Br. J. Cancer (1993), 68, 195-200 0 Macmillan Press Ltd., 1993 Br. J. Cancer (1993), 68, 195 200 Macmillan Press Ltd., Prognosis after resection of residual masses following chemotherapy for metastatic
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationChemotherapy for Urological Cancers
Chemotherapy for Urologic Cancers Matthew Rettig, MD Associate Professor Department of Medicine Division of Hematology-Oncology Department of Urology Medical Director, Prostate Cancer Program Institute
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationPatients and methods. Results
Journal of BUON 10: 195-200, 2005 2005 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Germ cell testicular tumors in clinical stage A and normal values of serum tumor markers post-orchiectomy:
More informationStrategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer
Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,
More informationBleomycin, Etoposide and CISplatin (BEP) Therapy
Bleomycin, Etoposide and CISplatin (BEP) Therapy INDICATIONS FOR USE: INDICATION ICD10 Regimen Code Adjuvant treatment of high risk (vascular invasion C62 00300a carcinoma) stage 1 nonseminoma germ cell
More informationGUIDELINES ON TESTICULAR CANCER
38 (Text updated March 2005) P. Albers (chairman), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, A. Horwich, O. Klepp, M.P. Laguna, G. Pizzocaro Introduction Compared with other types of cancer
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationESMO Consensus Empfehlungen 2017
ESMO Consensus Empfehlungen 2017 What s old, what s new, what s missing? Jörg Beyer, Klinik für Onkologie Offenlegung Interessenskonflikte 1. Anstellungsverhältnis oder Führungsposition Keine 2. Beratungs-
More informationData Supplement Table DS1: Pre-Treatment STM Assays to Evaluate Patients with CUP and Predict Chemotherapy Response
American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males with Germ Cell Tumors Gilligan, et al. SUPPLEMENTAL TABLES DS1-DS13 Data Supplement Table
More informationChemotherapy in Patients with Teratoma with Malignant Transformation
european urology 51 (2007) 1306 1312 available at www.sciencedirect.com journal homepage: www.europeanurology.com Testis Cancer Chemotherapy in Patients with Teratoma with Malignant Transformation Omar
More informationJemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
More informationAlicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015
Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationA population-based study of treatment guided by tumor marker decline in. 603 patients with metastatic non-seminomatous germ cell tumor - A report
A population-based study of treatment guided by tumor marker decline in 603 patients with metastatic non-seminomatous germ cell tumor - A report from the Swedish-Norwegian Testicular Cancer Group (SWENOTECA)
More informationsymposium article introduction symposium article
Annals of Oncology 17 (Supplement 5): v118 v122, 2006 doi:10.1093/annonc/mdj965 Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/ vinblastine/doxorubicin/cisplatin
More informationReceived February 17, 2014 / Received April 9, 2014
Neoplasma 62, 1, 2015 159 doi:10.4149/neo_2015_001 Management of patients with clinical stage I nonseminomatous germ cell testicular cancer: Active surveillance versus adjuvant chemotherapy single-centre
More informationNeodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
More informationPractical Application of PET adapted Therapy in Hodgkin Lymphoma
Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,
More informationThe evidence for and against neoadjuvant chemotherapy in localized STS
The evidence for and against neoadjuvant chemotherapy in localized STS Axel Le Cesne Gustave Roussy, Villejuif French Sarcoma Group EORTC, CTOS Académie de Médecine Drugs Practice, 2 nd of December 2016
More informationCurrent Approaches for Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Current Approaches for Limited Small Cell Lung Cancer Laurie Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Can we improve or personalize treatment? Limited Histology/molecular
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationProspective study evaluating a strategy of surgery alone and surveillance in FIGO stage I malignant ovarian germ cell tumor (KGOG 3033)
Prospective study evaluating a strategy of surgery alone and surveillance in FIGO stage I malignant ovarian germ cell tumor (KGOG 3033) Investigators/Collaborators: Jeong-Yeol Park, M.D., Ph.D. Department
More information